# Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

> **NCT00489905** · NA · COMPLETED · sponsor: **Hospital Authority, Hong Kong** · enrollment: 24 (estimated)

## Conditions studied

- Prostatic Neoplasms
- Bone Density

## Interventions

- **DRUG:** Zolderonic acid (Zometa)

## Key facts

- **NCT ID:** NCT00489905
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2008-05
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2013-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489905, "Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00489905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*